Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement.
BioArctic AB’s partner, Eisai, presented new data at the Alzheimer’s Association International Conference 2025, highlighting the efficacy and safety of lecanemab in treating early-stage Alzheimer’s disease. The findings from the phase 3 Clarity AD study and real-world evidence suggest that lecanemab can slow disease progression and maintain cognitive function over four years, with a consistent safety profile, offering promising long-term benefits for patients.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company that focuses on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company collaborates with partners like Eisai to advance its research and development efforts in this field.
Average Trading Volume: 249,249
Technical Sentiment Signal: Buy
Current Market Cap: SEK19.18B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Overview page.